Ultragenyx Pharmaceutical Inc. | Ownership
Companies that own Ultragenyx Pharmaceutical Inc.
Wellington Management Co. LLP
6,090,143
12.24%
-171,063
0.1%
06/30/2018
Capital Research & Management Co. (Global Investors)
5,755,563
11.56%
-158,884
0.09%
06/30/2018
The Vanguard Group, Inc.
3,976,375
7.99%
116,969
0.01%
06/30/2018
Capital Research & Management Co. (International Investors)
3,604,764
7.24%
13,718
0.32%
06/30/2018
BlackRock Fund Advisors
3,449,796
6.93%
83,818
0.02%
06/30/2018
Fidelity Management & Research Co.
3,441,112
6.91%
-485,424
0.03%
06/30/2018
T. Rowe Price Associates, Inc.
2,796,392
5.62%
544,691
0.03%
06/30/2018
SSgA Funds Management, Inc.
1,648,751
3.31%
-368,544
0.01%
06/30/2018
Columbia Wanger Asset Management LLC
1,291,107
2.59%
130,688
0.9%
06/30/2018
Federated Global Investment Management Corp.
1,224,734
2.46%
25,243
0.74%
06/30/2018
| Address |
60 Leveroni Court
Novato California 94949
United States
|
|
Employees
|
- |
| Website |
http://www.ultragenyx.com |
| Updated |
07/08/2019 |
| Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. |
